Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results HERCULES, Calif.—February 12, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: "2025 was a challenging year with geopolitical uncertainty and continued pressure on academic res ...

Market Overview - The proteomics market was valued at USD 29.92 billion in 2025 and is projected to grow to USD 58.66 billion by 2031, with a CAGR of 11.87% from 2026 to 2031, driven by precision medicine, chronic diseases, and demand for advanced analytical tools [1] - The role of proteomic analysis is expanding in drug discovery, biomarker identification, and disease pathway analysis, enhancing target validation and supporting targeted therapies [2] Regional Analysis - North America leads the proteomics market due to strong investment in biomedical research, advanced laboratory infrastructure, and the presence of major pharmaceutical and biotechnology companies [3] - Europe holds a significant market share, supported by active research programs and a focus on personalized medicine [4] - Asia-Pacific is emerging as a high-growth region, driven by expanding research capabilities and increasing government funding for life sciences [4] Market Trends - There is a growing adoption of proteomics in drug discovery to identify disease biomarkers and improve understanding of therapeutic targets [5] - The integration of proteomics with genomics is enhancing its role in precision medicine, enabling personalized approaches to disease diagnosis and treatment [6] Industry Segmentation - The proteomics market is segmented by components, technologies, and applications, including drug discovery and development [7] - Key technologies include mass spectrometry, chromatography, and next-generation sequencing [8] Competitive Landscape - The proteomics industry consists of established life science technology providers and specialized proteomics solution companies, focusing on expanding analytical capabilities and forming strategic collaborations [9]

Core Insights - BIO-key International, Inc. is launching its first office in India, located in Mumbai, to enhance its presence in the region and support local enterprises with identity and access management solutions [1][3] - The initiative aligns with the recent EU-India free trade agreement, which is the largest trade pact between the two economies, aimed at reducing tariffs and fostering economic cooperation in key sectors [2][5] - The partnership with Citadel Global will facilitate the delivery of BIO-key's IAM and biometric technologies, enhancing cybersecurity for large enterprises and financial institutions in India [4][5] Company Expansion - The new Mumbai office will be staffed by a local team and will leverage Citadel Global's market infrastructure for pre-sales engagement, deployment support, and customer success services [1][4] - BIO-key's portfolio includes various IAM solutions such as PortalGuard® IAM and passwordless authentication technologies, which will be made available through this partnership [4][7] Market Context - The expansion into India is part of a broader strategic initiative by international partners to strengthen technology ties with India following the EU-India free trade agreement, which is expected to create significant opportunities for trade in services and technology [5] - The Indian market is identified as a pivotal growth area for digital identity and cybersecurity innovation, with the collaboration expected to enhance compliance, customer trust, and operational efficiency for Indian enterprises [5][6]

Core Insights - BIO-key International, Inc. has formed a strategic partnership with Visualforma to enhance digital identity and access management for Portuguese municipal councils, focusing on cybersecurity and public digital services [1][5][7] Group 1: Partnership Details - Visualforma will spearhead the nationwide implementation of BIO-key's Identity and Access Management (IAM) and biometric authentication technologies across over 250 government organizations in Portugal [2] - The partnership aims to secure access to critical digital services, enhance cybersecurity controls, and ensure regulatory compliance within municipal administrations, educational institutions, and healthcare entities [2][4] Group 2: Implementation and Impact - The agreement includes deploying BIO-key's technologies in a major tourist city, addressing security and scalability needs for high-volume citizen and visitor services [3] - BIO-key's IAM and biometric solutions have already been operationalized in selected municipal environments, serving as reference architectures for further deployments [4] Group 3: Company Profiles - Visualforma is a well-established technology integrator in Portugal, recognized for its expertise in digital transformation and cybersecurity, with over 30 years of experience in the public sector [9] - BIO-key International specializes in biometric-centric IAM solutions, securing access for over 40 million users and offering various authentication methods, including phoneless and passwordless options [10]

Core Insights - The portfolio slightly outperformed the Russell Midcap® Value Index in Q4 2025 [2] Group 1 - The investment style has been consistently noted in prior quarterly portfolio letters [2]

Core Insights - Bio-Rad Laboratories, Inc. (BIO) is positioned for growth due to demand for its quality control and immunology products in Clinical Diagnostics, alongside international market expansion [1][10] - The company's stock has increased by 28.1% over the past six months, outperforming the industry which declined by 6.5% [2] - Bio-Rad's market capitalization stands at $8.44 billion, with earnings surpassing estimates in two of the last four quarters, averaging a surprise of 19.8% [2] Group 1: Growth Drivers - Clinical Diagnostics has returned to normalized growth post-pandemic, maintaining strong global market positions, particularly with the IH-500 blood typing system recognized as a gold standard [4][10] - The introduction of the IH-500 NEXT System in 2023 aims to address emerging laboratory demands, while the company invests in the new molecular diagnostics segment [5] - Clinical Diagnostics sales increased by 0.6% year-over-year in Q3 2025, with stable performance across product areas despite reimbursement challenges in China [6] Group 2: International Market Focus - Bio-Rad generates nearly 59% of its net revenues from international operations, with Europe being the largest market [7][10] - The company has direct distribution channels in over 36 countries, and while APAC markets face challenges, gradual improvements are anticipated [7] - The funding environment in key European markets is expected to improve modestly, offsetting some current business challenges [8] Group 3: Challenges - Macroeconomic conditions, including high raw material costs and geopolitical issues, have impacted Bio-Rad's performance, particularly in China [11] - The strengthening U.S. dollar negatively affects consolidated net sales, as international sales are primarily in local currencies [12] - The Zacks Consensus Estimate for Bio-Rad's 2025 earnings per share remains at $9.98, with revenues projected at $2.58 billion, reflecting a modest 0.7% increase from the previous year [13]

Core Viewpoint - Bio-Rad Laboratories, Inc. is actively engaging with analysts and investors at the J.P. Morgan's 44th Annual Healthcare Conference, indicating a focus on investor relations and market presence [1] Company Overview - Bio-Rad Laboratories, Inc. is recognized as a global leader in life science research and clinical diagnostics products [1] Event Details - The one-on-one meetings with analysts and investors will take place during the J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, from January 12-15, 2026 [1]

Core Insights - The portable microplate reader market is experiencing rapid growth driven by the increasing demand for point-of-care testing (POCT), ongoing investment in biopharmaceutical research, and the advancement of grassroots healthcare in emerging markets [4][10] - The market is highly concentrated, dominated by a few major players such as Thermo Fisher Scientific, BIO-RAD, and PerkinElmer, which have established strong market barriers through brand reputation and extensive sales networks [4][9] Market Trends and Drivers - The key drivers for the growth of the portable microplate reader market include the significant expansion of POCT demand, particularly in grassroots healthcare and emergency response scenarios [10] - Continuous investment in biopharmaceutical and life sciences research, along with advancements in detection technology towards miniaturization, automation, and user-friendliness, are also contributing to the market's growth [10] Opportunities and Challenges - Government support for precision medicine and public health emergency capabilities presents clear market opportunities, especially in infectious disease monitoring and bedside diagnostics [5] - However, increasing regulatory scrutiny and stringent medical device approval processes raise market entry barriers and costs, posing challenges for companies [5] Market Size and Growth Projections - According to QYResearch, the global portable microplate reader market is expected to reach USD 1.05 billion by 2031, with a compound annual growth rate (CAGR) of 4.5% in the coming years [5] Competitive Landscape - The top five manufacturers, including Thermo Fisher Scientific, BIO-RAD, and PerkinElmer, hold approximately 60% of the market share, indicating a highly concentrated competitive environment [9] Future Industry Opportunities - Future opportunities lie in upgrading grassroots healthcare systems in emerging markets and penetrating non-traditional clinical fields such as veterinary, food safety, and environmental monitoring [12] - The integration of artificial intelligence and IoT technologies for smart interpretation and remote data management is expected to create new application scenarios and business models [12]

Core Insights - BIO-key International, Inc. has secured a significant deployment with a major defense-sector security organization in the Middle East, enhancing its presence in high-assurance government and defense environments [1][2]. Group 1: Deployment Details - The contract is one of BIO-key's largest security-sector deployments in the region, aimed at strengthening access security and streamlining credential management through biometric-based authentication without reliance on mobile devices or hardware tokens [2]. - The deployment is facilitated by a strategic partnership with Cloud Distribution, a Saudi-based Value-Added Distributor, which combines BIO-key's IAM solutions with local cybersecurity expertise [3]. Group 2: Strategic Commitment - The deployment underscores BIO-key's commitment to supporting national security and critical infrastructure protection in the Middle East, reflecting the trust in its technology for securing sensitive environments [4]. Group 3: Company Overview - BIO-key is a leader in biometric-centric, multi-factor identity and access management (IAM) software, securing access for over 40 million users and offering various authentication options, including phoneless, tokenless, and passwordless solutions [5].

Core Insights - Bio-Rad Laboratories reported its third-quarter earnings, achieving revenue of $653 million, which represents a modest year-over-year increase of 0.5%. Net income, on a non-GAAP basis, rose by 8% to just under $61 million, translating to an adjusted earnings per share of $2.26. Despite these results beating analyst expectations, the stock experienced a decline of over 3% following the report, which was more significant than the S&P 500's 0.9% drop [1][2][3][6]. Financial Performance - Revenue for Q3 was $653 million, a slight increase of 0.5% year-over-year [2]. - Non-GAAP net income increased by 8% to just under $61 million, with an adjusted earnings per share of $2.26 [2]. - Analyst consensus had projected revenue of $652.2 million and adjusted earnings of $1.95 per share, indicating that Bio-Rad's performance exceeded these expectations [3]. Market Reaction - The stock market reacted negatively to Bio-Rad's earnings report, leading to a decline of over 3% in its share price, despite the company beating both revenue and earnings estimates [1][6]. Future Guidance - Bio-Rad maintained its guidance for 2025, forecasting revenue growth to be flat to 1% above the 2024 results. The company also indicated that its adjusted operating margin is expected to be between 12% and 13% [3].